{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Interferon-%CE%B2", "query": { "intervention": "Interferon-β" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 11, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Interferon-%CE%B2&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-02T14:20:40.394Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00811395", "title": "Long Term Safety of Teriflunomide When Added to Interferon-Beta or Glatiramer Acetate in Patients With Multiple Sclerosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Sclerosis" ], "interventions": [ { "name": "Teriflunomide", "type": "DRUG" }, { "name": "Placebo (for teriflunomide)", "type": "DRUG" }, { "name": "Interferon-β [IFN-β]", "type": "DRUG" }, { "name": "Glatiramer Acetate [GA]", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 182, "start_date": "2007-10", "completion_date": "2010-04", "has_results": true, "last_update_posted_date": "2012-12-31", "last_synced_at": "2026-09-02T14:20:40.394Z", "location_count": 1, "location_summary": "Bridgewater, New Jersey", "locations": [ { "city": "Bridgewater", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT00811395" }, { "nct_id": "NCT01939002", "title": "Characterize Flu-like Symptoms in Relapsing Multiple Sclerosis Patients Transitioning From Non-Pegylated Interferon Beta (IFN-β) Therapies to Peginterferon Beta-1a (BIIB017)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Relapsing Multiple Sclerosis" ], "interventions": [ { "name": "BIIB017", "type": "DRUG" }, { "name": "naproxen", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Biogen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 251, "start_date": "2013-11", "completion_date": "2015-11", "has_results": true, "last_update_posted_date": "2017-01-25", "last_synced_at": "2026-09-02T14:20:40.394Z", "location_count": 38, "location_summary": "Gilbert, Arizona • Phoenix, Arizona • Tucson, Arizona + 34 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Boulder", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT01939002" }, { "nct_id": "NCT00107861", "title": "Interferon-Beta Gene Transfer (Ad.hIFN-β) as Treatment for Refractory Colorectal Carcinoma With Liver Metastases", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Colorectal Carcinoma", "Metastases" ], "interventions": [ { "name": "Ad.hIFN-β (BG00001, IDEC-201)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Biogen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 44, "start_date": "2005-05", "completion_date": "2006-09", "has_results": false, "last_update_posted_date": "2009-07-14", "last_synced_at": "2026-09-02T14:20:40.394Z", "location_count": 2, "location_summary": "La Jolla, California • Dallas, Texas", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00107861" }, { "nct_id": "NCT04732949", "title": "Study to Assess Efficacy and Safety of Inhaled Interferon-β Therapy for COVID-19", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Severe Acute Respiratory Syndrome Coronavirus 2", "COVID-19" ], "interventions": [ { "name": "SNG001", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Synairgen Research Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 623, "start_date": "2021-01-12", "completion_date": "2022-02-10", "has_results": true, "last_update_posted_date": "2023-03-27", "last_synced_at": "2026-09-02T14:20:40.394Z", "location_count": 6, "location_summary": "Tucson, Arizona • St. Petersburg, Florida • Detroit, Michigan + 3 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "St. Petersburg", "state": "Florida" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Minneapolis", "state": "Minnesota" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04732949" }, { "nct_id": "NCT00299962", "title": "Gene Therapy for Pleural Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Pleural Mesothelioma", "Metastatic Pleural Effusions" ], "interventions": [ { "name": "Adenoviral-mediated Interferon-beta", "type": "BIOLOGICAL" }, { "name": "SCH 721015", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "University of Pennsylvania", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 17, "start_date": "2006-03", "completion_date": "2009-10", "has_results": false, "last_update_posted_date": "2020-03-18", "last_synced_at": "2026-09-02T14:20:40.394Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00299962" }, { "nct_id": "NCT00436826", "title": "A Phase 2 Study of Cladribine Add-on to Interferon-beta (IFN-beta) Therapy in Multiple Sclerosis (MS) Subjects With Active Disease (ONWARD)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Sclerosis" ], "interventions": [ { "name": "Cladribine", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Interferon-beta (IFN-beta)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "EMD Serono Research & Development Institute, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 172, "start_date": "2006-11-30", "completion_date": "2012-03-31", "has_results": true, "last_update_posted_date": "2020-10-12", "last_synced_at": "2026-09-02T14:20:40.394Z", "location_count": 21, "location_summary": "Cullman, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 18 more", "locations": [ { "city": "Cullman", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Boulder", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT00436826" }, { "nct_id": "NCT00819000", "title": "Therapy Optimization in Multiple Sclerosis (MS)", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Multiple Sclerosis" ], "interventions": [ { "name": "Glatiramer Acetate, IFN-beta 1a (IM), IFN-beta 1a (Subcutaneous), and IFN-beta 1b", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Teva Neuroscience, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2878, "start_date": "2008-12", "completion_date": "2013-01", "has_results": false, "last_update_posted_date": "2013-01-29", "last_synced_at": "2026-09-02T14:20:40.394Z", "location_count": 3, "location_summary": "Swartz Creek, Michigan • Columbus, Ohio • Carnegie, Pennsylvania", "locations": [ { "city": "Swartz Creek", "state": "Michigan" }, { "city": "Columbus", "state": "Ohio" }, { "city": "Carnegie", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00819000" }, { "nct_id": "NCT00489489", "title": "Phase II Study of Teriflunomide as Adjunctive Therapy to Interferon-beta in Subjects With Multiple Sclerosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Sclerosis" ], "interventions": [ { "name": "Teriflunomide", "type": "DRUG" }, { "name": "Placebo (for Teriflunomide)", "type": "DRUG" }, { "name": "Interferon-β", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 118, "start_date": "2007-05", "completion_date": "2009-06", "has_results": true, "last_update_posted_date": "2012-11-06", "last_synced_at": "2026-09-02T14:20:40.394Z", "location_count": 1, "location_summary": "Bridgewater, New Jersey", "locations": [ { "city": "Bridgewater", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT00489489" }, { "nct_id": "NCT05028634", "title": "Safety Study to Evaluate Immune Response of Vaccines in Participants With Relapsing Forms of Multiple Sclerosis Who Receive Ozanimod Compared to Non-Pegylated Interferon (IFN)-β or No Disease Modifying Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Multiple Sclerosis", "Multiple Sclerosis, Relapsing-Remitting" ], "interventions": [ { "name": "Tetanus, diphtheria, and acellular pertussis vaccine", "type": "BIOLOGICAL" }, { "name": "Pneumococcal polysaccharide vaccine", "type": "BIOLOGICAL" }, { "name": "Seasonal influenza vaccine", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 63, "start_date": "2021-11-11", "completion_date": "2023-11-15", "has_results": true, "last_update_posted_date": "2025-02-11", "last_synced_at": "2026-09-02T14:20:40.394Z", "location_count": 29, "location_summary": "Palo Alto, California • Colorado Springs, Colorado • Southington, Connecticut + 26 more", "locations": [ { "city": "Palo Alto", "state": "California" }, { "city": "Colorado Springs", "state": "Colorado" }, { "city": "Southington", "state": "Connecticut" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Port Charlotte", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05028634" }, { "nct_id": "NCT05400122", "title": "Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer", "overall_status": "SUSPENDED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Colorectal Cancer", "Hematologic Malignancy", "Rectum Cancer", "Acute Myeloid Leukemia", "Myelodysplastic Syndromes", "Acute Lymphoblastic Leukemia", "Chronic Myeloid Leukemia", "Chronic Lymphocytic Leukemia", "Hodgkin Lymphoma", "Non Hodgkin Lymphoma", "Myeloproliferative Syndrome", "Plasma Cell Myeloma", "Gastric Cancer", "Esophageal Cancer", "Esophagus Cancer", "Gastric Cancer, Metastatic", "Unresectable Esophageal Cancer", "Metastatic Esophageal Cancer" ], "interventions": [ { "name": "Vactosertib", "type": "DRUG" }, { "name": "Fludarabine Phosphate", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "IL-2", "type": "DRUG" }, { "name": "Natural Killer Cells", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "David Wald", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2022-09-09", "completion_date": "2027-06-01", "has_results": false, "last_update_posted_date": "2026-07-14", "last_synced_at": "2026-09-02T14:20:40.394Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT05400122" } ] }